53 results
8-K
EX-99.1
GRTS
Gritstone Bio Inc
13 Jan 20
Other Events
6:15am
with bluebird bio for tumor-specific targets and natural T cell receptors for cellular-based therapies BiSpecific Antibodies Tumor-specific binding through … identification of HLA-peptide targets and high-quality antibodies Manufacturing and Testing Facility ~43,000 sq. ft. fully integrated GMP
8-K
EX-99.1
GRTS
Gritstone Bio Inc
27 Sep 23
Entry into a Material Definitive Agreement
4:07pm
containing Spike plus other viral targets with an approved vaccine against COVID-19 —
— Contract is part of ‘Project NextGen,’ an initiative … Spike plus other viral targets to protect against COVID-19. The agreement, which is valued at up to $433 million, was awarded as part of ‘Project
8-K
EX-99.1
GRTS
Gritstone Bio Inc
1 May 20
Gritstone Oncology Announces the Appointment of Dr. Elaine V. Jones as Chair of the Board of Directors
4:02pm
to Gritstone as we pioneer entirely novel classes of products based on our deep understanding of T cells and T cell targets.”
Dr. Jones was most … pioneering immunotherapies utilizing these T cell targets in cancer patients. I am honored to be appointed as chair and look forward to working closely
8-K
EX-99.1
GRTS
Gritstone Bio Inc
8 Nov 23
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
4:06pm
, which combines self-amplifying mRNA (samRNA) with novel B and T cell targets, as a leading potential next-generation vaccine platform for COVID-19 … these studies highlighted the potential of Gritstone’s next-generation samRNA-based approach, which incorporates Spike plus other viral targets (“Spike
8-K
EX-99.1
GRTS
Gritstone Bio Inc
4 Jan 22
Other Events
5:21pm
across a wide set of non-spike epitopes, including many validated T cell targets in convalescent individuals, demonstrating the potential for variant … -proof immunity
Proportion of responses to TCE targets assessed by ELISpot:
36% Nucleoprotein (N)
22% Membrane (M)
42% ORF3a
A boost to pre-existing T
424B4
4zn5hs3h1 qaoqi6
25 Apr 19
Prospectus supplement with pricing info
4:06pm
DRS
2ig2pfjs
28 Dec 18
Draft registration statement
12:00am
10-K
f6d6 9u3hmxzc
28 Mar 19
Annual report
4:01pm
8-K
EX-99.1
wrc762h8 b5v
22 Jul 22
Entry into a Material Definitive Agreement
5:11pm
424B4
f3wvjpasng87bc4s9k
1 Oct 18
Prospectus supplement with pricing info
12:00am
8-K
EX-99.1
id8na6mmt
10 Aug 22
Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors
4:08pm
8-K
q9rzcr82
27 Sep 23
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-99.1
iztdnxm3kcp46spkd
17 Aug 21
Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern
7:00am
8-K
EX-99.1
mju78hvw0
13 Dec 19
Other Events
5:02pm
8-K
EX-99.1
kwo9p a0983wr
25 Oct 22
Entry into a Material Definitive Agreement
4:35pm